Test formula
OtherPartially hydrolyzed formula with synbiotics
NCT Number: NCT06943469
The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.
Interested in participating?
Request Info1 day–14 day
All sexes
Interventional
Not applicable
AZ Sint-Jan Brugge-Oostende AV - Campus Sint-Jan, Bruges, Belgium
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
or b. For the randomized formula-fed groups only: infant is exclusively or predominantly formula-fed in the 24 hours prior to enrollment, with formula feeding representing at least 75% of total daily feeds. The decision to introduce formula feeding was independently made by the parents before enrollment.
Exclusion criteria
Partially hydrolyzed formula with synbiotics
Intact protein formula without synbiotics
Time frame: At 3 months of age
TransEpidermal water loss will be measured using a validated non-invasive technique.
Time frame: From enrollment to 12 months of age
Cumulative incidence of AD is based on physician diagnosis using the United Kingdom Working Party (UKWP) diagnosis criteria.
Time frame: From enrollment to 12 months of age
Epidermal water loss will be measured using a validated non-invasive technique.
Time frame: From enrollment to 12 months of age
Skin hydration will be measured with a corneometer device.
Time frame: From 3 months to 12 months of age
SCORAD (SCORing for Atopic Dermatitis), scores range from 0 to 103, with higher scores indicating higher atopic dermatitis severity
Time frame: From enrollment to 12 months of age
Use of medication to treat AD and other symptoms will be collected via parent self-reported questionnaire.
Time frame: From enrollment to 12 months of age
Concentration of skin cytokines such as IL4 and IL5 using immunoassays
Time frame: From enrollment to 12 months of age
Concentration of skin natural moisturizing factors such as Pyrrolidone carboxylic acid, using HPLC
Time frame: From enrollment to 12 months of age
Concentration of skin stratum corneum lipids such as ceramides, cholesterol and triacylglycerol using mass spectrometry
Time frame: From enrollment to 12 months of age
Overall skin microbiome composition and diversity using next-generation sequencing
Time frame: From enrollment to 12 months of age
Levels of skin metabolites using targeted or untargeted approaches.
Time frame: From enrollment to 6 months of age
Levels of plasma proteins using mass cytometry or immunoassaysand immunoassays.
Time frame: From enrollment to 6 months of age
Levels of immune cell populations using mass cytometry or immunoassays
Time frame: At 12 months of age
Specific IgE antibodies will be measured using Phadiatop infant®.
Time frame: From enrollment to 12 months of age
Overall fecal microbiota composition, diversity, different bacteria taxa and microbiota community types assessed using next generation sequencing (NGS) technology
Time frame: From enrollment to 12 months of age
Levels of fecal metabolites using targeted or untargeted approaches.
Time frame: From enrollment to 12 months of age
Levels of fecal markers of immune health and inflammation such as total secretory IgA (sIgA), calprotectin, and α-1-antitrypsin assessed by ELISA.
Time frame: From enrollment to 12 months of age
Number of participants with Physician-diagnosed allergic manifestations.
Time frame: At enrollment and 4 months of age
Infant Gastrointestinal Symptom Questionnaire (IGSQ), scores range from 13 to 65, with higher scores indicating higher gastrointestinal discomfort.
Time frame: From enrollment to 12 months of age
Weight (g and z-scores)
Time frame: From enrollment to 12 months of age
Length (cm and z-scores)
Time frame: From enrollment to 12 months of age
Head circumference (cm and z-scores)
Time frame: From enrollment to 13 months of age
Incidence of adverse events
Contact information is provided by the study sponsor or research team.
Société des Produits Nestlé (SPN)
Industry
Synbiotics in Partially Hydrolysed Formula for Improved skiN Barrier Function in Infants at Risk for Allergy (SPHINX Study)
Acronym: SPHINX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07730788
Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Romans-sur-Isère, Drôme, France
View Trial DetailsNCT07659756
Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Zurich, Switzerland
View Trial DetailsNCT07544862
Atopic Dermatitis (AD), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Beijing, Beijing Municipality, China
View Trial DetailsNCT07298395
Atopic Dermatitis (AD), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial Details